Hyperion sales and marketing update
On a Feb. 4 conference call regarding FDA's approval of Ravicti glycerol phenylbutyrate, Hyperion said it estimated a mean gross price of $250,000-$290,000 annually per patient for the drug. Company management said that about 40% of patients are on Medicaid, which includes a 23% rebate. The prodrug of phenylacetic acid was approved this month for the management of chronic urea cycle disorders in patients at least two years of age. The company, which did not provide sales guidance, expects to launch in the U.S. by the end of April.
The company also said it has implemented the UCD Support Services call center for Ravicti prescription, intake and distribution, reimbursement adjudication, patient financial support and ongoing compliance support (see BioCentury, Feb. 4). ...